• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Progyny Adds Pelvic Floor Therapy, Continuing to Close Gaps in Care Across Women's Health

    6/24/25 9:10:00 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care
    Get the next $PGNY alert in real time by email

    NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced that it is adding pelvic floor therapy to its comprehensive offering of women's health and family building solutions. With the expansion of its network of specialty trained women's health providers, and the addition of digital therapy, the company is further deepening its commitment to increasing the accessibility of specialized, timely care across the spectrum from preconception and maternal health to midlife and menopause.

    One in three women experience pelvic floor issues, with one in five needing to undergo surgery to treat their pelvic floor disorder (UCM). While most commonly associated with postpartum care, pelvic floor complications impact women as early as young adulthood and span through menopause and later into life. When left untreated, not only can pelvic pain interfere with quality of life that can lead to reduced performance at work and absenteeism, but it can also result in avoidable health complications and increased downstream medical costs. For instance, conditions such as endometriosis and sexual dysfunction are linked to untreated pelvic health issues, which can lead to infertility.

    "This is another moment when Progyny is stepping up to help women identify and seek care for basic health needs that are going undiagnosed and untreated due to lack of education, lack of care access, and lack of the right benefits coverage," said Dr. Janet Choi, Progyny Chief Medical Officer. "By enabling access to specialty trained providers and offering educational support tools through a cost effective and comprehensive benefit, we are providing impactful clinical solutions as opposed to a ‘sweep it under the rug' approach to women's health."

    Virtual and In-Person Support Options for Treatment and Coaching

    Progyny members will have expanded access to both in-person and virtual care options. Through this integrated and multi-pronged approach, members will benefit from earlier interventions for pelvic conditions, reducing fragmentation, and helping avoid delays that could lead to higher acuity treatments, surgeries, or increased healthcare costs for employers. Urinary incontinence alone has been associated with costing the healthcare industry $20 billion a year (NIH).

    Progyny welcomes Origin and Hinge Health to its offering. With Origin, Progyny members can seamlessly access Origin's nationwide in-network pelvic floor physical therapy, both in-person and virtually. Origin provides evidence-based treatment for the full spectrum of pelvic health needs—from common concerns like leaky bladder, painful sex, and postpartum recovery, to more complex conditions including hysterectomy recovery, endometriosis, PCOS, and chronic pelvic pain. Origin's specialized physical therapists provide evidence-based care that addresses both physical and mental health through every stage of life, whether you're preparing for childbirth, recovering from surgery, or managing ongoing symptoms.

    "Origin has been leading the way in destigmatizing the shame that still exists around the biggest milestones in women's lives and working to make pelvic floor therapy part of the standard of care," said Carine Carmy, CEO & Co-Founder, Origin. "Whether it's postpartum recovery or painful sex in menopause, our goal is to make personalized, whole-body care accessible to women wherever they are in their health journey."

    With Hinge Health, members will receive digital care supported by physical therapists specializing in pelvic health and musculoskeletal (MSK) care. Each individual will follow a personalized plan with guided exercises targeting their unique symptoms – including but not limited to pelvic pain, a lack of pelvic strength or bladder control, and issues associated with menopause. By engaging regularly with these exercises, members build sustainable habits and make positive lifestyle adjustments that are proven to relieve symptoms and improve overall health.

    "By combining expert clinical care and advanced technology, we are removing barriers to care access and enabling individuals to experience better health outcomes," said Aaryn Pure, Chief Commercial Officer, Hinge Health. "Our comprehensive pelvic health program, now offered in conjunction with Progyny, will bring their members high-quality pelvic health support as part of their broader women's health experience."

    For more information on Progyny and its pelvic floor offering, visit www.progyny.com.

    About Progyny

    Progyny (NASDAQ:PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients and physicians.

    Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.

    Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit www.progyny.com.

    For Further Information, Please Contact:



    Media:

    Alexis Ford

    [email protected]

    Investors:

    James Hart

    [email protected]



    Primary Logo

    Get the next $PGNY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PGNY

    DatePrice TargetRatingAnalyst
    1/20/2026$30.00Mkt Perform → Mkt Outperform
    Citizens JMP
    1/8/2026$34.00Hold → Buy
    Truist
    12/9/2025$29.00Overweight
    Barclays
    11/12/2025$30.00Sector Weight → Overweight
    KeyBanc Capital Markets
    7/8/2025$28.00Market Perform → Outperform
    Leerink Partners
    12/2/2024$17.00Overweight → Neutral
    Analyst
    11/13/2024$26.00 → $19.00Buy → Hold
    Truist
    9/19/2024Mkt Outperform → Mkt Perform
    JMP Securities
    More analyst ratings

    $PGNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Progyny upgraded by Citizens JMP with a new price target

    Citizens JMP upgraded Progyny from Mkt Perform to Mkt Outperform and set a new price target of $30.00

    1/20/26 8:45:21 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny upgraded by Truist with a new price target

    Truist upgraded Progyny from Hold to Buy and set a new price target of $34.00

    1/8/26 9:26:52 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Barclays initiated coverage on Progyny with a new price target

    Barclays initiated coverage of Progyny with a rating of Overweight and set a new price target of $29.00

    12/9/25 8:52:58 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    SEC Filings

    View All

    Progyny Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Progyny, Inc. (0001551306) (Filer)

    1/12/26 8:12:20 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny Inc. filed SEC Form 8-K: Leadership Update

    8-K - Progyny, Inc. (0001551306) (Filer)

    12/17/25 8:00:09 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 144 filed by Progyny Inc.

    144 - Progyny, Inc. (0001551306) (Subject)

    12/4/25 9:41:35 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2025 Results Report

    NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period and full year ended December 31, 2025, after the close of the market on Thursday, February 26, 2026. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using t

    2/12/26 2:46:53 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny to Discuss Updated Financial Expectations at Upcoming JP Morgan Healthcare Conference

    NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced that the Company is participating in the 44th Annual JP Morgan Healthcare Conference, where it intends to discuss its updated expectations for the quarter and year ending December 31, 2025. "As the fourth quarter progressed, we were pleased to see that member engagement has paced favorably as compared to the guidance we issued in November," said Pete Anevski, Progyny's Chief Executive Officer. "Accordingly, we now expect our fourth quarter results for revenue, net income and Adjusted EBITDA to be slightly abo

    1/12/26 8:00:00 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    New Men's Health Research from Progyny Challenges Conventional Beliefs about Fertility Knowledge and Action

    NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in family building solutions, today announced new men's health research exploring experiences and views on fertility. The findings shed light on how men in the U.S. view their role in the fertility journey and the barriers that prevent many from getting the care they need for successful conception. The research, collected in partnership with Dynata – the world's largest first-party data company for insights, activation, and measurement – captured insights from more than 1,000 U.S. men ages 18–55. While most men reported recognizing fertility as a shared responsibility between partners, social stigma, f

    11/20/25 9:23:00 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Anevski Peter bought $1,930,896 worth of shares (79,500 units at $24.29), increasing direct ownership by 13% to 680,251 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    11/17/25 8:22:02 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Executive Chairman Schlanger David J bought $2,202,330 worth of shares (150,000 units at $14.68), increasing direct ownership by 192% to 228,269 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    12/26/24 5:35:03 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    CHIEF EXECUTIVE OFFICER Anevski Peter bought $3,034,084 worth of shares (209,500 units at $14.48), increasing direct ownership by 90% to 441,463 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    12/26/24 5:31:32 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman Schlanger David J covered exercise/tax liability with 2,171 shares, decreasing direct ownership by 0.90% to 238,462 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    1/5/26 6:00:26 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    CHIEF EXECUTIVE OFFICER Anevski Peter covered exercise/tax liability with 6,009 shares, decreasing direct ownership by 0.88% to 674,242 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    1/5/26 5:58:10 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    PRESIDENT Sturmer Michael E covered exercise/tax liability with 33,028 shares, decreasing direct ownership by 11% to 255,205 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    1/5/26 5:53:41 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Leadership Updates

    Live Leadership Updates

    View All

    Progyny CEO Named World Economic Forum Champion for Women's Health

    NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced that CEO Pete Anevski has been honored with the recognition as a Champion for Women's Health by the World Economic Forum (the Forum) and the Global Alliance for Women's Health (GAWH). The community of Champions is a distinguished group of global leaders who are playing a critical role in driving advocacy efforts, shaping policies, fostering innovation, and unlocking investments to advance women's health. The exclusive Champions community spans diverse sectors, industries, and geographies, and includes figures such as: Helen Clark, former

    10/7/25 9:30:50 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny Appoints Two Renowned Women's Health Experts to Medical Advisory Board

    NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced the appointment of Morehouse School of Medicine's Regional Dean for Seattle and Puget Sound's Dr. Gloria Richard-Davis – a double-board certified physician in Obstetrics and Gynecology and Reproductive Endocrinology and Infertility, a fellow of the American College of Obstetricians & Gynecologists (FACOG), and a Menopause Society Certified Practitioner (MSCP) – and Columbia University's Dr. Whitney Booker – a double-board certified physician in Obstetrics and Gynecology and Maternal-Fetal Medicine – to its Medical Advisory Board. "As Pr

    5/14/25 9:05:48 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny Names Healthcare Veterans Melissa Cummings as Chief Operating Officer and Geoffrey Clapp as Chief Product Officer

    NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Progyny (NASDAQ:PGNY), a global leader in women's health and family building, today announced the appointments of Melissa Cummings as the company's first Chief Operating Officer (COO) and Geoffrey Clapp as its first Chief Product Officer (CPO). The additions to the executive leadership team will extend Progyny's ability to further drive operational excellence, advance innovation in product design and member experience, and continue to address care gaps and unmet needs across the spectrum of family building and women's health – from preconception to fertility and menopause. "Progyny has established itself at the forefront of building and del

    4/17/25 9:36:59 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Financials

    Live finance-specific insights

    View All

    Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2025 Results Report

    NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period and full year ended December 31, 2025, after the close of the market on Thursday, February 26, 2026. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using t

    2/12/26 2:46:53 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny, Inc. Announces Third Quarter 2025 Results

    Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and Near 100% Retention of Existing BaseRecord $156.0 Million in Operating Cash Flow Generated over the First Nine Months of 2025Board Authorizes Up to $200 Million in Share Repurchase Program NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended September 30, 2025 ("the third quarter of 2025"), as compared to the th

    11/6/25 4:01:00 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny, Inc. Announces Details for Its Third Quarter 2025 Results Report

    NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period ended September 30, 2025 after the close of the market on Thursday, November 6, 2025. The company will host a conference call at 4:45 P.M. Eastern Time (1:45 P.M. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcod

    10/23/25 1:08:44 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Progyny Inc.

    SC 13G/A - Progyny, Inc. (0001551306) (Subject)

    12/6/24 10:11:35 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Progyny Inc.

    SC 13G/A - Progyny, Inc. (0001551306) (Subject)

    11/14/24 4:31:23 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G/A filed by Progyny Inc. (Amendment)

    SC 13G/A - Progyny, Inc. (0001551306) (Subject)

    2/14/24 6:29:49 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care